The FDA has proposed removing oral phenylephrine from over-the-counter nasal decongestants after a review found it to be ineffective. Other safe and effective treatments are available for nasal congestion. In other news, a study found that only 55.5% of allergists accept Medicaid, potentially creating barriers to care. Additionally, efforts are being made to train physician assistants in allergy care to meet growing patient demand. Combined treatments of inhaled corticosteroids and formoterol were found to improve asthma outcomes, while barzolvolimab showed promise in improving chronic inducible urticaria. These findings were highlighted in the top stories in allergy/asthma.
Source link
FDA proposal on oral phenylephrine; Medicaid barriers to care
